Overcoming Zika-Dengue cross-reactivity: the highly specific immunoassays your lab needs
In the global battle against Zika virus, serological cross-reactivity with Dengue is a major challenge for academics, epidemiologists and pharmaceutical companies alike. Novel immunoassays can now overcome this problem and could prove a real game-changer in Zika...
The Right Tools for Rubella
Rubella remains a significant pathogen worldwide, with 100,000 cases of congenital rubella syndrome estimated to occur every year. Vaccines to Rubella are highly safe and have effectively eliminated endemic infection in many developed countries, yet inadequate...
Visualising viral infection with immunofluorescence microscopy
Following the latest immunofluoresence data for our Zika and Dengue antibodies, we’ve invited VRS to write a short blog one of their areas of expertise: The applications of immunofluorescence microscopy in studying viruses. A lot of what we know about biology...
New Immunofluorescence Data for our Flavivirus Antibodies
We recently teamed-up with Virology Research Services (VRS) to test a large panel of our viral antibodies in immunofluorescence applications. This work was funded by the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) through the...
Challenges to Effective Yellow Fever Diagnostics
Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...
Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity
Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...Why Zika virus’s cross-reactivity with Dengue might be hampering your research
Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the discovery and...
How The Native Antigen Company responds to the WHO list of priority infectious diseases
In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...
Native Antigen release a panel of serotype specific monoclonal antibodies
There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...
A silver-lining from Zika virus?
Zika virus (ZIKV) is an enveloped single stranded RNA virus. It is a member of the Flavivirus genus of the family Flaviviridae, which is transmitted to humans primarily through the bite of the Aedes aegypti mosquito. In 2015, a major outbreak of Zika virus was...
Congenital CMV – a problem ignored?
Congenital CMV infection – a serious problem that receives little attention Cytomegalovirus (CMV) is a human specific double stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus can be...